Reciprocal influence of HIV and HCV infections in co-infected patients and the involvement of HAART  by Tamalet, C. & Colson, Ph.
EDITORIAL
Reciprocal inﬂuence of HIV and HCV infections in co-infected patients
and the involvement of HAART
C. Tamalet and Ph. Colson
Laboratory of Virology, Timone Hospital, Marseille, France
Accepted 25 April 2002
The reciprocal inﬂuence of HIV-HCV co-infection was established prior to the era of
highly active retroviral therapy (HAART) and continues to be a topic of debate, including
the question of which infection to treat ﬁrst.
Owing to common transmission pathways, HIV–
HCV co-infection frequently occurs among hemo-
philiacs and injecting drug users (60–90%). Over-
all, at least a third of patients infected with HIV are
also infected with hepatitis C virus (HCV) [1]. The
reciprocal inﬂuence of these two viral diseases on
prognosis was questioned and extensively studied
before the era of highly active antiretroviral ther-
apy (HAART), and is still relevant with the advent
of triple combination therapy [2]. The controversy
concerning the effects of hepatitis C on the pro-
gression of HIV-1 infection has been settled con-
clusively by the Swiss cohort study [3], which
involved a large number of patients (1157 HIV–
HCV co-infected) and demonstrated that increas-
ed probability of progression to a newAIDS-deﬁn-
ing clinical event or to death was independently
associated with HCV seropositivity, and therefore,
that HCV infection worsens the course of HIV
infection.
The inﬂuence of HIV infection before HAART
on HCV infection is no longer a matter of debate,
as cohort studies have consistently shown that
HIV infection accelerates the clinical and histologic
course of chronic hepatitis C, increasing HCV
RNA levels [4] and the severity of liver disease,
and hastening the progression to cirrhosis [5,6].
The impact of HAART on the course of HCV-
related chronic hepatitis and HCV replication is
controversial.
The article by Perez Cano et al. in the September
2002 issue of the journal is timely, as the evaluation
conducted by those investigators was performed
with up to 12months of follow-up, and showed
that CD4þ cell count and HIV viremia did not
inﬂuence the course of untreated HCV infection
in 45 patients, and that HAART did not modify the
HCV viremia levels. In agreement with most stu-
dies, the authors have demonstrated a slight
decrease (non-signiﬁcant) of HCV viral load and
alanine aminotransferase (ALT) levels in HIV–
HCV-co-infected patients treated with HAART
[7–9]. Other investigators have reported a transient
or persistent increase in HCV load during HAART
[10,11], whereas clearance of HCV RNA serum
levels during HAART has been reported once [12].
Interestingly, Perez-Cano et al. found, like
others, that improvement in the immune status
due to HAART was not sufﬁcient to reduce HCV
viral titers.
The adverse effect of HAART on HCV infection
must be taken into account, in particular for pro-
tease inhibitors which inhibit the cytochrome P450
system [13], increase ALT levels and induce liver
injury. Therefore, worsening of hepatitis, and evo-
lution towards cirrhosis due to the immune
restoration obtained with antiretroviral therapy,
are hypothetical risks.
The question of which infection to treat ﬁrst has
been debated, some authors claiming that elimina-
tion (clearance) of HCV should be considered a
prerequisite for a sustained anti-HIV response
[14]. Conversely, according to recent consensus
criteria [15,16], treatment should focus on HIV
ﬁrst, and then on HCV only in patients with a
CD4 count greater than 200–300 cells/mL and/or
severe histologic lesions (ﬁbrosis score of F2–F4 or
signiﬁcant inﬂammatory activity); moreover,
treatment rather than biopsies may be recom-
mended in patients with HCV genotypes 2/3
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[16]. Additionally, treating HCV may decrease the
liver toxicity of anti-HIV medication.
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